In This Section      
Print This Page

Current News Releases

Current News Releases

Released: June 21, 2017


Johns Hopkins researchers report that a molecular diagnostic test accurately distinguishes among the three most common causes of vaginitis, an inflammation of  vaginal tissue they say accounts for millions of visits to medical clinics and offices in the U.S. each year.

Released: June 19, 2017


Experimenting with mice, neuroscientists at Johns Hopkins Medicine report new evidence that the eye’s iris in many lower mammals directly senses light and causes the pupil to constrict without involving the brain.

Released: June 16, 2017


Jed Fahey, assistant professor of medicine at the Johns Hopkins University School of Medicine, is available to comment on new research showing that sulforaphane—a compound naturally found in broccoli—could potentially manage blood glucose levels in people with type II diabetes.

Released: June 14, 2017

Infectious disease experts say nearly a fifth of prescriptions were unnecessary


A study examining the impact of antibiotics prescribed for nearly 1500 adult patients admitted to The Johns Hopkins Hospital found that adverse side effects occurred in a fifth of them, and that nearly a fifth of those side effects occurred in patients who didn’t need antibiotics in the first place.

Released: June 13, 2017


Officials at Johns Hopkins Medicine announced today an expansion of its five-year affiliation with Allegheny Health Network (AHN) and Highmark, which provide health care services and insurance to people in Western Pennsylvania, West Virginia and Delaware. The newly expanded relationship aims to support the care of patients with rare and complex adult and pediatric cancers and some organ-transplant patients, widen the portfolio of cancer clinical trials available to AHN’s patients, facilitate participation in medical education, and collaborate on genomic sequencing and precision medicine research.

Released: June 12, 2017


After more than 44 years of unparalleled service to Johns Hopkins, Ronald R. Peterson has announced plans to retire as president of Johns Hopkins Health System and executive vice president of Johns Hopkins Medicine at the end of 2017.

Released: June 12, 2017

Assessments not keeping up with clinical trial advances


A group of researchers from several institutions in the USA, including Johns Hopkins Medicine, reports that its review of 22 clinical trials of fragile X syndrome (FXS) suggests the need for a wider use of newer and improved treatment outcome measurement tools for this and other several neurodevelopmental disorders. FXS is the most common inherited form of intellectual disability and the most common form of autism associated with a single gene mutation.

Released: June 9, 2017


Increasing our understanding of bladder cancer pathogenesis, using immune surveillance to eradicate local tumors and micrometastases, and attempting to identify molecular subtypes in bladder cancers to support personalized therapies: These are some of the exciting research initiatives being recognized by the Greenberg Bladder Cancer Institute 2017 Research Grants Awards.

Released: June 9, 2017


In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called ‘mismatch repair’ genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda). In a report on the findings, which led the U.S. Food and Drug Administration to approve expanded use of pembrolizumab for patients, the researchers also say they found evidence that the immune responses closely aligned with mutations found in their cancers. The report is published online in the June 8 issue of the journal Science.

Released: June 7, 2017

New strategy tested in animals could improve cancer immunotherapies


Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells’ defensive properties while switching on a robust anticancer immune response in mice. Experiments with the tiny, double-duty “immunoswitch” found it able to dramatically slow the growth of mouse melanoma and colon cancer and even eradicate tumors in test animals, the researchers report.

Released: June 1, 2017


Combining two checkpoint inhibitors, drugs that remove inhibitory signals and restore the immune system’s ability to fight cancer, may be effective in shrinking melanoma tumors or preventing their growth in some patients who previously received standard therapy, according to new research results from the Johns Hopkins Bloomberg~Kimmel Institute. (ASCO Abstract 9520).

Released: May 31, 2017


The Johns Hopkins University and Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that they have extended their drug discovery collaboration through an exclusive licensing agreement.

Released: May 30, 2017

'Price Gouging' Is Worst for Minorities and Uninsured


An analysis of billing records for more than 12,000 emergency medicine doctors across the United States shows that charges varied widely, but that on average, adult patients are charged 340 percent more than what Medicare pays for services ranging from suturing a wound to interpreting a head CT scan.

Released: May 30, 2017

Researchers have found that immune cells latently infected with HIV can proliferate, carrying the virus along with cellular DNA


Researchers at Johns Hopkins Medicine report new evidence that immune cells infected with a latent form of human immunodeficiency virus (HIV) are able to proliferate, replenishing the reservoir of virus that is resistant to antiretroviral drug therapy.

Released: May 23, 2017

Discovery of personalized immunotherapy approach has roots at Johns Hopkins and its Bloomberg~Kimmel Institute laboratories and clinics


Today, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes.

Released: May 22, 2017


In a recent paper published online in the journal Critical Care Medicine, researchers at the Johns Hopkins Armstrong Institute of Patient Safety and Quality led a study that demonstrated that health care providers can take steps to curb ventilator-associated events.

Released: May 18, 2017


You might remember him as Hawkeye Pierce on “M*A*S*H,” as Senator Vinick on “The West Wing,” or as the host of PBS’ “Scientific American Frontiers” for more than a decade. This Friday, Alan Alda will be visiting Johns Hopkins to share his thoughts on the importance of clear science communications to faculty, staff and students. Since 2009, he has been running the Alan Alda Center for Communicating Science at Stonybrook University, and has been a proponent of science communication and making science more accessible to everyone.

Released: May 18, 2017

The process may cause more harm than good


Johns Hopkins researchers say they have identified a new way that cells in the brain alert the rest of the body to recruit immune cells when the brain is injured. The work was completed in mouse models that mimic infection, stroke or trauma in humans.

Released: May 16, 2017


In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it may be effective in preserving the vision of people with wet age-related macular degeneration (AMD). AMD is a leading cause of vision loss in the U.S., affecting an estimated 1.6 million Americans. The disease is marked by growth of abnormal blood vessels that leak fluid into the central portion of the retina called the macula, which we use for reading, driving and recognizing faces.

Released: May 10, 2017


Using gene sequencing tools, scientists from Johns Hopkins Medicine and the University of British Columbia have found a set of genetic mutations in samples from 24 women with benign endometriosis, a painful disorder marked by the growth of uterine tissue outside of the womb. The findings, described in the May 11 issue of The New England Journal of Medicine, may eventually help scientists develop molecular tests to distinguish between aggressive and clinically “indolent,” or non-aggressive, types of endometriosis.